控制基孔肯雅热病毒的疫苗和治疗选择。
Vaccine and Therapeutic Options To Control Chikungunya Virus.
机构信息
Division of Vector-Borne Diseases, Centers for Diseases Control and Prevention, Fort Collins, Colorado, USA
出版信息
Clin Microbiol Rev. 2017 Dec 13;31(1). doi: 10.1128/CMR.00104-16. Print 2018 Jan.
Abstract
Beginning in 2004, chikungunya virus (CHIKV) went from an endemic pathogen limited to Africa and Asia that caused periodic outbreaks to a global pathogen. Given that outbreaks caused by CHIKV have continued and expanded, serious consideration must be given to identifying potential options for vaccines and therapeutics. Currently, there are no licensed products in this realm, and control relies completely on the use of personal protective measures and integrated vector control, which are only minimally effective. Therefore, it is prudent to urgently examine further possibilities for control. Vaccines have been shown to be highly effective against vector-borne diseases. However, as CHIKV is known to rapidly spread and generate high attack rates, therapeutics would also be highly valuable. Several candidates are currently being developed; this review describes the multiple options under consideration for future development and assesses their relative advantages and disadvantages.
摘要
从 2004 年开始，基孔肯雅病毒（CHIKV）从一种局限于非洲和亚洲的地方性病原体，发展成为一种全球性病原体，导致周期性暴发。鉴于 CHIKV 引起的暴发仍在继续且不断扩大，必须认真考虑确定疫苗和疗法的潜在选择。目前，这方面没有许可产品，控制完全依赖于使用个人防护措施和综合病媒控制，而这些措施的效果非常有限。因此，迫切需要紧急审查进一步控制的可能性。疫苗对虫媒疾病非常有效。然而，由于 CHIKV 传播迅速，发病率高，因此治疗方法也非常有价值。目前正在开发几种候选药物；本综述描述了正在考虑用于未来开发的多种选择，并评估了它们的相对优势和劣势。
相似文献
1
Vaccine and Therapeutic Options To Control Chikungunya Virus.控制基孔肯雅热病毒的疫苗和治疗选择。
Clin Microbiol Rev. 2017 Dec 13;31(1). doi: 10.1128/CMR.00104-16. Print 2018 Jan.
2
Therapeutics and vaccines against chikungunya virus.针对基孔肯雅病毒的治疗方法和疫苗。
Vector Borne Zoonotic Dis. 2015 Apr;15(4):250-7. doi: 10.1089/vbz.2014.1681.
3
Chikungunya virus infections: time to act, time to treat.基孔肯雅热病毒感染：行动起来，及时治疗。
Curr Opin Virol. 2017 Jun;24:25-30. doi: 10.1016/j.coviro.2017.03.016. Epub 2017 Apr 14.
4
Prophylactic strategies to control chikungunya virus infection.控制基孔肯雅病毒感染的预防策略。
Virus Genes. 2021 Apr;57(2):133-150. doi: 10.1007/s11262-020-01820-x. Epub 2021 Feb 15.
5
Antibody-based therapeutic interventions: possible strategy to counter chikungunya viral infection.基于抗体的治疗干预：应对基孔肯雅病毒感染的可能策略。
Appl Microbiol Biotechnol. 2020 Apr;104(8):3209-3228. doi: 10.1007/s00253-020-10437-x. Epub 2020 Feb 19.
6
Antiviral therapeutics for chikungunya virus.基孔肯雅热病毒的抗病毒疗法。
Expert Opin Ther Pat. 2020 Jun;30(6):467-480. doi: 10.1080/13543776.2020.1751817. Epub 2020 Apr 17.
7
Molecular epidemiology, evolution and phylogeny of Chikungunya virus: An updating review.基孔肯雅病毒的分子流行病学、进化与系统发育：一篇综述更新
Infect Genet Evol. 2016 Jul;41:270-278. doi: 10.1016/j.meegid.2016.04.006. Epub 2016 Apr 13.
8
51 years in of Chikungunya clinical vaccine development: A historical perspective.基孔肯雅热临床疫苗研发 51 年：历史视角。
Hum Vaccin Immunother. 2019;15(10):2351-2358. doi: 10.1080/21645515.2019.1574149. Epub 2019 Apr 2.
9
Monoclonal Antibodies as Prophylactic and Therapeutic Agents Against Chikungunya Virus.单克隆抗体作为抗基孔肯雅病毒的预防和治疗药物
J Infect Dis. 2016 Dec 15;214(suppl 5):S506-S509. doi: 10.1093/infdis/jiw324.
10
Regulatory considerations in development of vaccines to prevent disease caused by Chikungunya virus.预防基孔肯雅病毒所致疾病的疫苗研发中的监管考量
Vaccine. 2017 Sep 5;35(37):4851-4858. doi: 10.1016/j.vaccine.2017.07.065. Epub 2017 Jul 29.
引用本文的文献
1
Chikungunya virus and other emerging arthritogenic alphaviruses.基孔肯雅病毒及其他新出现的致关节炎甲病毒
Nat Rev Microbiol. 2025 May 7. doi: 10.1038/s41579-025-01177-8.
2
Vaccines Against Urban Epidemic Arboviruses: The State of the Art.针对城市流行性虫媒病毒的疫苗：现状
Viruses. 2025 Mar 6;17(3):382. doi: 10.3390/v17030382.
3
Identification of potential vaccines for use with microarray patches in low- and middle-income countries: An assessment from the Vaccine Innovation Prioritisation Strategy Alliance.低收入和中等收入国家中与微阵列贴片联合使用的潜在疫苗的识别：来自疫苗创新优先战略联盟的评估。
Vaccine. 2025 May 10;55:126996. doi: 10.1016/j.vaccine.2025.126996. Epub 2025 Mar 24.
4
Strategic vaccination responses to Chikungunya outbreaks in Rome: Insights from a dynamic transmission model.罗马针对基孔肯雅热疫情的策略性疫苗接种应对措施：基于动态传播模型的见解
PLoS Negl Trop Dis. 2024 Dec 9;18(12):e0012713. doi: 10.1371/journal.pntd.0012713. eCollection 2024 Dec.
5
Attenuated Getah virus confers protection against multiple arthritogenic alphaviruses.减毒型盖塔病毒可对多种致关节炎甲病毒提供保护。
PLoS Pathog. 2024 Nov 18;20(11):e1012700. doi: 10.1371/journal.ppat.1012700. eCollection 2024 Nov.
6
Current Epidemiological Status of Chikungunya Virus Infection in East Africa: A Systematic Review and Meta-Analysis.东非基孔肯雅病毒感染的当前流行病学状况：一项系统综述和荟萃分析
J Trop Med. 2024 Oct 25;2024:7357911. doi: 10.1155/2024/7357911. eCollection 2024.
7
Chikungunya virus vaccine: a decade of progress solving epidemiological dilemma, emerging concepts, and immunological interventions.基孔肯雅病毒疫苗：解决流行病学困境、新出现概念及免疫干预措施的十年进展
Front Microbiol. 2024 Jul 22;15:1413250. doi: 10.3389/fmicb.2024.1413250. eCollection 2024.
8
The evolutionary and molecular history of a chikungunya virus outbreak lineage.基孔肯雅热病毒爆发谱系的进化和分子历史。
PLoS Negl Trop Dis. 2024 Jul 26;18(7):e0012349. doi: 10.1371/journal.pntd.0012349. eCollection 2024 Jul.
9
Engineered Antiviral Sensor Targets Infected Mosquitoes.工程化抗病毒传感器靶向感染的蚊子。
CRISPR J. 2023 Dec;6(6):543-556. doi: 10.1089/crispr.2023.0056.
10
Developing a Prototype Pathogen Plan and Research Priorities for the Alphaviruses.开发一种用于甲病毒的病原体方案和研究重点的原型。
J Infect Dis. 2023 Oct 18;228(Suppl 6):S414-S426. doi: 10.1093/infdis/jiac326.
本文引用的文献
1
The complexity and cost of vaccine manufacturing - An overview.疫苗生产的复杂性与成本——概述
Vaccine. 2017 Jul 24;35(33):4064-4071. doi: 10.1016/j.vaccine.2017.06.003. Epub 2017 Jun 21.
2
Investigation of twenty selected medicinal plants from Malaysia for anti-Chikungunya virus activity.研究马来西亚的二十种药用植物的抗基孔肯雅病毒活性。
Int Microbiol. 2016 Sep;19(3):175-182. doi: 10.2436/20.1501.01.275.
3
Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus.减毒活疫苗和载体疫苗可保护非人灵长类动物免受基孔肯雅病毒感染。
JCI Insight. 2017 Mar 23;2(6):e83527. doi: 10.1172/jci.insight.83527.
4
Curcumin inhibits Zika and chikungunya virus infection by inhibiting cell binding.姜黄素通过抑制细胞结合来抑制寨卡病毒和基孔肯雅病毒感染。
Antiviral Res. 2017 Jun;142:148-157. doi: 10.1016/j.antiviral.2017.03.014. Epub 2017 Mar 24.
5
2016 International meeting of the Global Virus Network.2016年全球病毒网络国际会议。
Antiviral Res. 2017 Jun;142:21-29. doi: 10.1016/j.antiviral.2017.03.005. Epub 2017 Mar 16.
6
Discovery of a novel antiviral agent targeting the nonstructural protein 4 (nsP4) of chikungunya virus.发现一种靶向基孔肯雅病毒非结构蛋白4（nsP4）的新型抗病毒剂。
Virology. 2017 May;505:102-112. doi: 10.1016/j.virol.2017.02.014. Epub 2017 Feb 23.
7
Mutation of the N-Terminal Region of Chikungunya Virus Capsid Protein: Implications for Vaccine Design.基孔肯雅病毒衣壳蛋白N端区域的突变：对疫苗设计的启示
mBio. 2017 Feb 21;8(1):e01970-16. doi: 10.1128/mBio.01970-16.
8
Therapy with CTLA4-Ig and an antiviral monoclonal antibody controls chikungunya virus arthritis.使用CTLA4-Ig和抗病毒单克隆抗体进行治疗可控制基孔肯雅病毒关节炎。
Sci Transl Med. 2017 Feb 1;9(375). doi: 10.1126/scitranslmed.aah3438.
9
Characterization of β-d--Hydroxycytidine as a Novel Inhibitor of Chikungunya Virus.β-D-羟基胞苷作为基孔肯雅病毒新型抑制剂的特性研究
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.02395-16. Print 2017 Apr.
10
Antiviral effect of compounds derived from the seeds of Mammea americana and Tabernaemontana cymosa on Dengue and Chikungunya virus infections.来自美国山竹子种子和聚伞树种子的化合物对登革热病毒和基孔肯雅病毒感染的抗病毒作用。
BMC Complement Altern Med. 2017 Jan 18;17(1):57. doi: 10.1186/s12906-017-1562-1.
Zotero 插件